Indian Panel Flaws Biosimilar Humira Package Insert
This article was originally published in Scrip
An Indian expert panel has flagged a clutch of deficiencies in the package insert of Reliance Life Sciences' biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), including some inconsistencies around data and dosing.
You may also be interested in...
Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.